The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback